Streetbeat News

SPRC

SciSparc Ltd.

https://scisparc.com

Industry

Biotechnology

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Open

0.22

Mkt cap

2.5M

Volume

203K

High

0.24

P/E Ratio

-0.04

52-wk high

14.22

Low

0.22

Div yield

N/A

52-wk low

0.21

Clearmind Medicine has announced the publication of a patent application under the PCT for a ketamine-based combination treatment. This development could enhance their intellectual property portfolio and potentially lead to new treatment options.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 8:28 pm

SciSparc shares declined following the announcement of a Standby Equity Agreement with a Selling Shareholder, allowing for the sale of up to $20 million in Ordinary Shares.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 4:03 pm

SciSparc has filed for the sale of up to 21 million ordinary shares under a $20 million SEPA agreement, with shares priced at 97% of market value. The company may receive up to $8.82 million from this sale.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:46 pm

Affirm Holdings, Inc. (AFRM) shares surged 18% in pre-market trading due to better-than-expected Q4 earnings and positive Q1 guidance. Other notable pre-market movers include BioCardia, Inc. (BCDA) with a 109.5% gain after FDA clearance, and Big Lots, Inc. (BIG) with a 30.5% decline amid bankruptcy concerns.

Portfolio Pulse from Avi Kapoor

August 29, 2024 | 9:37 am

SciSparc Ltd. has granted Polyrizon Ltd. global rights to its SCI-160 pain therapy program in a deal worth up to $6 million. SciSparc will receive $3 million in Polyrizon securities and potential milestone fees of $3 million in cash.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 1:00 pm

MIRA Pharmaceuticals shares surged 44.8% in pre-market trading after announcing a successful rat study with Ketamin-2. Other notable pre-market movers include MEDIROM Healthcare, Prestige Wealth, and Tevogen Bio, among others.

Portfolio Pulse from Avi Kapoor

August 26, 2024 | 9:58 am

SciSparc shares rose following the submission of an Investigational New Drug (IND) application to the FDA for their drug candidate SCI-110.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 8:18 pm

SciSparc Ltd. has submitted an IND application to the FDA for a Phase IIb clinical trial of SCI-110, aimed at treating Tourette Syndrome. The trial will be conducted at multiple international sites, including Yale School of Medicine.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 8:10 pm

SciSparc Ltd. (NASDAQ:SPRC) has enrolled the first five patients in its clinical trial for a CBD-based treatment for autism spectrum disorder (ASD) in children. The trial, conducted at Soroka Medical Center in Israel, aims to assess the efficacy and safety of SciSparc's proprietary SCI-210 drug. The company plans to enroll 60 subjects and eventually sell the treatment in Israel and other countries.

Portfolio Pulse from Jelena Martinovic

August 20, 2024 | 7:28 pm

SciSparc has enrolled the first five patients in its clinical trial for the SCI-210 treatment, marking a significant milestone in its research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 8:12 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.